IMPORTANT - EIN Presswire is proud to announce the launch of its AI-powered press release generator. Try it now!

There were 238 press releases posted in the last 24 hours and 394,097 in the last 365 days.

KaloBios Now Current on SEC Periodic Filings

Submits outstanding reports for 2016 first and second quarters

/EIN News/ -- BRISBANE, Calif., Sept. 23, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced the filing with the U.S. Securities and Exchange Commission (SEC) of the company’s Forms 10-Q for the three months ended March 31, 2016, and for the three and six months ended June 30, 2016.

KaloBios is now current with its SEC periodic reporting requirements. Achieving this milestone is crucial to the company’s turnaround.

“Among the many accomplishments of the new management team at KaloBios, becoming current with our SEC filings reflects our focus and momentum in achieving important financial and non-financial milestones to build investor and investment community confidence,” said Cameron Durrant, MD, chairman and CEO. “We continue to apply the same energy and expertise to accomplishing our strategic priorities to build our financial foundation and accelerate our pipeline programs.”

KaloBios emerged from bankruptcy on June 30, 2016, with new management and a transformational strategy, including its Responsible Pricing Model.

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab (formerly KB003) and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit

Forward-Looking Statements

This release contains forward-looking statements that are intended to be subject to protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,”  “accelerate,” “continue,” and similar expressions identify forward-looking statements, including, without limitation, statements related to expectations regarding the Company’s product candidates; the Company’s opportunity to benefit from the application of our Responsible Pricing Model; and expectations for the Company’s future financial position. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the uncertainties inherent in the development and launch of any new pharmaceutical product; our ability to successfully and timely complete clinical trials for our drug candidates in clinical development; our ability to obtain the necessary U.S. and international regulatory approvals for our drug candidates and to qualify for or benefit from various regulatory incentives; the scope and validity of intellectual property and other competitive protection for our drug candidates; our ability to identify, in-license and acquire additional product candidates or to form partnerships for the sale, licensing, collaborative development or marketing of our existing product candidates; our ability to maintain or engage third-party manufacturers to manufacture, supply, store and distribute supplies of our drug candidates for our clinical trials; our lack of profitability and the need for additional capital to operate our business; and the success of any product; and the various risks and uncertainties described in the "Risk Factors" and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.


Kim Sutton Golodetz
O: 212-838-3777

Bruce Voss
O: 310-691-7100

Lisa Guiterman
O: 301-217-9353
C: 202-330-3431

Primary Logo